A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating with Decitabine in Pediatric Relapsed and Refractory Acute Leukemias

To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.

Start Date31 Dec 2025

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT06854003

/ Not yet recruitingPhase 2IIT

A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

This study aims to evaluate the efficacy and safety of an induction regimen combining Bendamustine, Rituximab, Cytarabine (AraC), and Zanubrutinib (BRAZAN), followed by maintenance therapy with Zanubrutinib and Rituximab with or without Sonrotoclax in participants with Mantle Cell Lymphoma (MCL).
The names of the study drugs involved in this study are:
* bendamustine (a type of alkylating agent)
* rituximab (a type of monoclonal antibody)
* cytarabine (a type of antineoplastic)
* zanubrutinib (a type of kinase inhibitor)
* sonrotoclax (a type of BCL2 inhibitor)

Start Date01 Aug 2025

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT06317662

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.

Start Date26 Apr 2025

Sponsor / Collaborator

National Cancer Institute

100 Clinical Results associated with Cytarabine

100 Translational Medicine associated with Cytarabine

100 Patents (Medical) associated with Cytarabine

30,439

Literatures (Medical) associated with Cytarabine

31 Dec 2025·Annals of Medicine

Efficacy and safety of low-dose TBI combined MAC regimen for HSCT in high-risk AML patients with active disease

Article

Author: Fan, Yang ; Liu, Lirong ; Xie, Yaping ; Shi, Pengfei ; Huang, Xilian ; Chen, Can ; Tan, Junfeng ; Gao, Daquan ; Chen, Kuang ; Xu, Ying ; Qian, Shenxian

BACKGROUNDThe management of high-risk acute myeloid leukaemia (AML) remains challenging, highlighting the need for innovative conditioning strategies beyond current regimens.METHODSIn the present single-arm study, a FACT regimen comprised of low-dose total body irradiation (TBI) with fludarabine, cytarabine and cyclophosphamide was employed to treat cytogenetically high-risk AML patients exhibiting pre-transplant active disease. This clinical trial is registered in the Chinese Clinical Trial Registry with the registration number ChiCTR2000035111.RESULTSIn this study, 21 high-risk AML patients with pre-transplant disease statuses including primary induction failure, relapse and measurable residual disease positivity, were enrolled to undergo FACT conditioning. The FACT group demonstrated a 1-year non-relapse mortality (NRM) rate of 9.5%, indicating a similar level of safety and tolerability among the conditioning regimens. The estimated cumulative incidence of grade 2-4 acute graft-versus-host disease (GVHD) at one year was 30.7%. Additionally, the cumulative incidence of chronic GVHD was 36.0% at one year and increased to 43.0% at two years.CONCLUSIONSThe FACT regimen is an effective myeloablative conditioning (MAC) strategy for high-risk AML patients, potentially reducing relapse risk without increasing NRM, warranting further research.

01 Apr 2025·Clinical Lymphoma Myeloma and Leukemia

De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma

Article

Author: Duggan, Peter ; Owen, Carolyn ; Stewart, Colin ; Chua, Neil ; Shafey, Mona ; Puckrin, Robert ; Perry, Sarah ; Street, Lesley E ; Stewart, Douglas A

BACKGROUNDThiotepa-based autologous stem cell transplantation (ASCT) improves survival in primary central nervous system lymphoma (PCNSL), but > 30% of patients are unable to undergo ASCT following commonly used intensive induction regimens.METHODSThis retrospective population-based study included consecutive patients ≥ 18 years old with PCNSL who were intended for ASCT in Alberta, Canada between 2011 and 2022. A reduced-intensity induction protocol was further abbreviated in 2018 to decrease toxicity and expediate ASCT by incorporating rituximab, procarbazine, and only 2 doses of high-dose methotrexate and 1 cycle of high-dose cytarabine before consolidation with thiotepa-busulfan conditioning. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan-Meier method.RESULTSAmong 71 patients with median age 58 years (range 26-72), ASCT was completed in 56 (79%), with the transplantation rate among patients > 60 years old increasing by 30% following the abbreviation of induction therapy. With median follow-up time 3.9 years, 4-year PFS and OS were 69% (95% CI 56%-79%) and 80% (95% CI 67%-88%) for all patients and 75% (95% CI 57%-86%) and 85% (95% CI 68%-93%) for ASCT recipients, respectively. There was 1 death due to treatment-related mortality during induction and none after ASCT, including among 17 transplanted patients > 60 years old.CONCLUSIONAn abbreviated induction regimen followed by thiotepa-busulfan-based ASCT achieves high transplantation rates with low risks of relapse and treatment-related mortality, thereby providing an effective treatment strategy for PCNSL.

01 Apr 2025·Prostaglandins, Leukotrienes and Essential Fatty Acids

Long-chain omega-3 polyunsaturated fatty acids are associated with brain connectivity and mood in young adults with subthreshold depression: A preliminary study

Article

Author: Faulkner, Paul ; Gibson, E Leigh ; Dyall, Simon C

BACKGROUNDThe long-chain omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have beneficial effects in depression, and these effects may be mediated via changes in functional brain connectivity. However, little is known about these effects in those with subthreshold depression.METHODS15 Participants aged 18-29 years with Patient Health Questionnaire-8 (PHQ-8) scores ≥ 4 and Generalised Anxiety Disorder Assessment-7 (GAD-7) scores ≥ 5, underwent resting-state functional magnetic resonance imaging. Whole-brain, seed-based connectivity analyses were performed using bilateral orbitofrontal cortex (OFC) and amygdala seeds. Omega-3 and -6 PUFA status was assessed from dried bloodspot analysis of %DHA, %EPA, Omega-3 Index (calculated as the sum of DHA plus EPA expressed as a percentage of the total measured fatty acids and a correction applied as dried blood spot samples were used instead of erythrocytes) and ratio of the omega-6 PUFA arachidonic acid (ARA) to EPA (ARA/EPA).RESULTSPHQ-8 scores indicated subthreshold depression (mean = 10.0; SD = 4.2) and were negatively associated with DHA levels and Omega-3 Index. Significant negative associations were also identified between connectivity of the OFC with the angular gyrus and DHA and Omega-3 Index, while weaker connectivity of these regions was associated with lower PHQ-8 and GAD-7 scores. DHA and Omega-3 Index values were significantly associated with greater connectivity of the amygdala with the posterior cingulate cortex, which was also associated with lower PHQ-8 scores.CONCLUSIONSHigher omega-3 PUFA status in young adults with moderate, but mean subthreshold depression was associated with lower depression rating scores and altered functional connectivity of brain regions shown to play a role in the neurobiology of depression.

228

News (Medical) associated with Cytarabine

06 Mar 2025

·moleculin.com

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

New patents will extend coverage to major markets outside the U.S., expanding upon existing U.S. claims Affirms expectations for an initial data readout of the phase 3 MIRACLE trial for the second half of 2025 HOUSTON, March 6, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received a Notice of Intent to Grant for the European patent application titled, “Method of Reconstituting Liposomal Annamycin“. The grant is subject to payment of fees and completion of final amendments and formalities. Such grant will enhance the global exclusivity of Annamycin with the potential to be a next generation, non-cardiotoxic treatment for certain cancers. When issued, the patent claims will cover methods of making liposomal Annamycin suspension as well as the resulting compositions for use in the treatment of cancers, with a base patent term currently extending until June 2040, subject to extension to account for time required to fulfill requirements for regulatory approval. Moleculin’s novel drug candidate is being positioned to become the first ever non-cardiotoxic anthracycline to be approved and is currently being developed for the treatment of acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases (STS lung mets). Additional preclinical studies performed at a world-renowned cancer center indicate Annamycin may be a potential treatment for many more other types of cancers. The new chemical entity uses a unique lipid-based delivery technology and has shown the potential to be used in a wide range of cancers. In addition to the expected European patent and previously issued U.S. patents, Moleculin has additional patent applications related to Annamycin pending in the U.S., Europe and in major jurisdictions worldwide. Wally Klemp, Chairman and CEO of Moleculin, said “Acknowledgment by the European Patent Office of the innovation underlying Annamycin is an important milestone for Moleculin, underscoring the importance and proprietary nature of the innovation that makes this next generation anthracycline possible. We expect Europe to be an important market for Annamycin and look forward to making an important new treatment available to patients in this region. This enhancing of our exclusivity for Annamycin is exciting when coupled with our continued expectation for an initial data readout for the MIRACLE trial in the second half of 2025.” The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the achievements of each of the milestones in this press release. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@jtcir.com View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-announces-additional-annamycin-patent-allowances-to-enhance-global-exclusivity-302393600.html SOURCE Moleculin Biotech, Inc.

Phase 3

05 Mar 2025

·firstwordpharma.com

Why In8bio took its time moving into autoimmunity

Last year was a rough one for cell and gene therapy companies. The expensive treatments faced stiff competition from more accessible options in crowded indications — prompting a broad industry migration out of oncology and into the autoimmune space, particularly for cell therapy developers (see – Vital Signs: The four big ideas that flopped in 2024).Unlike several of its peers — including Adicet Bio, IGM Biosciences, Caribou Biosciences and Nkarta — IN8bio did not change disease course last year with its allogeneic gamma-delta T cell therapy. While the biotech did pause its clinical-stage glioblastoma programmes to conserve cash, its lead candidate, INB-100, remains in Phase I testing for acute myeloid leukaemia (see – Spotlight On: Five reasons lupus research momentum is mounting).But now, after taking the necessary time to select the right candidate with a thought-out clinical and commercial strategy, IN8bio is ready to make its move into autoimmunity. Taking the TCE tackThe biotech unveiled a gamma-delta T cell engager (TCE) platform on Monday, as well as the first candidate to be built with the new technology: INB-619, a CD19-targeted TCE that could help treat leukaemias, lymphomas, and yes, autoimmune diseases. "When everybody else moved with cellular therapy into the autoimmune space, we didn't do that," IN8bio CEO William Ho told FirstWord. "We took our time, used our knowledge about biology, used our knowledge about diseases and gamma-delta T-cell biology, to create something where we think we can have some real advantages."Some of the cell therapy firms that jumped into the autoimmune space last year are already facing headwinds. Kyverna Therapeutics raised the second-largest biotech IPO last year on the strength of its inflammatory disease–directed CAR-T, but has since lost much of its valuation. A data disclosure in June for KYV-101 suggested some risk of recurrence following treatment — potentially undercutting one of the major purported advantages of cell therapy in settings like lupus (see – Vital Signs: Biotech's best (and worst) in class for 2024).In addition, while cell therapies make sense for patients who are dying of cancer, the treatments — which must be given at certified treatment centres, carry the risk of serious toxicities and can only be administered after lymphodepleting regimens — may not be attractive options to patients with autoimmune conditions like lupus. "When you look at the literature, a very large population of autoimmune patients are women between the ages of 20 and 45 — women of maternal age," Ho said. Because the lymphodepleting agent cytarabine can cause permanent ovarian damage, he speculated that only women who are very sick with an autoimmune disease would be willing to try a cell therapy.With those treatment barriers in mind, IN8bio decided that its gamma-delta T cell therapy wasn't the right horse to bet on for autoimmunity — but lucky for the biotech, it had something else in the works that was better suited for the disease space."It was somewhat fortuitous that we had developed this internal programme," Ho said of IN8bio's TCE. "By going to an engager — by using our knowledge and know-how about the gamma-delta T cell — we created a potentially off-the-shelf therapy that requires no lymphodepletion, that can be re-dosed, that drives deep B-cell depletion."The gamma-delta advantage?Like many B-cell depleting agents, IN8bio's candidate targets CD19. But rather than binding the T-cell antigen CD3 like most TCEs, INB-619's other arm engages with an undisclosed gamma-delta T-cell receptor. The hope, Ho said, is that by avoiding CD3 engagement, the programme will lead to lower IL-6 secretion, and in turn, a lower risk of two of the most severe side effects associated with CAR-Ts and TCEs: cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome.Some other potential advantages of INB-619 over traditional TCEs is its ability to drive high levels of T cell expansion and activate both major gamma-delta T cell subsets, which could help make the treatment more durable. IN8bio is evaluating the programme in preclinical studies, and is looking for a partner to move INB-619 into IND-enabling trials.

Cell TherapyPhase 1ImmunotherapyIPO

03 Mar 2025

·moleculin.com

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

HOUSTON, March 3, 2025 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced its abstract has been accepted for poster presentation at the Acute Leukemias XIX (ISALXIX) International Symposium being held March 16-19, 2025 in Munich, Germany. Details for the poster presentation are as follows: Abstract: P002Session: Clinical Studies in AML and ALLTitle: Liposomal Annamycin in Combination with Cytarabine for Treatment of Acute Myeloid Leukemia (AML)Presenting Author: Cristina Papayannidis, MD, PhD, Adjunct professor, Department of Medical and Surgical Sciences, University of Bologna, Bologna Italy For more information about the ISALXIX International Symposium, visit the event website. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin, is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The Company is initiating the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108), a pivotal, adaptive design Phase 3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC, for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study is subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications. For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775MBRX@jtcir.com View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-abstract-accepted-for-poster-presentation-at-the-acute-leukemias-xix-isalxix-international-symposium-302389270.html SOURCE Moleculin Biotech, Inc.

Phase 3

100 Deals associated with Cytarabine

External Link

KEGG	Wiki	ATC	Drug Bank
D00168	Cytarabine	L01BC01	DB00987

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lymphoma	Japan	Nippon Shinyaku Co., Ltd.	11 Nov 2002
Acute Lymphoblastic Leukemia	Japan	Nippon Shinyaku Co., Ltd.	18 Jan 2000
Acute Myeloid Leukemia	Japan	Nippon Shinyaku Co., Ltd.	18 Jan 2000
Bladder Cancer	Japan	Nippon Shinyaku Co., Ltd.	15 Feb 1984
Bile Duct Neoplasms	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Breast Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Colonic Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Gallbladder Neoplasms	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Liver Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Lung Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Ovarian Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Pancreatic Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Rectal Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Stomach Cancer	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973
Uterine Neoplasms	Japan	Nippon Shinyaku Co., Ltd.	24 Apr 1973

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Myeloid Leukemia	Phase 1	Canada	Cephalon, Inc.	01 Oct 2007
Acute Myeloid Leukemia	Discovery	Canada	Cephalon, Inc.	01 Oct 2007
Philadelphia chromosome positive chronic myelogenous leukemia	Discovery	United States	Teva Parenteral Medicines, Inc.	17 Jun 1969

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04914676 (CTgov)	Phase 2	Acute Myeloid Leukemia	5	Cytarabine (Prospective HiDAC Treatment (HiDAC 123))	eziibpevgr(npxmfzhjdv) = wquljunoot kegnsuskir (zaidkgaftv, tcbmjxeyhz - rkgegkqoat) View more	-	16 Jan 2025
				Cytarabine (Historical HiDAC Treatment (HiDAC 135))	eziibpevgr(npxmfzhjdv) = rbvxvxnhyf kegnsuskir (zaidkgaftv, klybzplksl - mzuoazbzyf) View more
NCT00801216 (SCNSL1, CTgov)	Phase 2	Central Nervous System Diseases \| B-Cell Lymphoma	40	etoposide+cyclophosphamide+carmustine+Rituximab+methotrexate+Thiotepa+cytarabine	(vouyiwatai) = lwankeiyqz nsnbhluwnq (yxhliqhjmz, owofdbjwtl - ytsxuqeufg) View more	-	10 Dec 2024
NCT03709758 (ASH2024) Manual	Phase 1	Acute Myeloid Leukemia First line	44	Venetoclax + Daunorubicin + Cytarabine	(nkgkuwfrue) = 100 mg/d venetoclax was the MTD for pts treated with consol ara-C at 3 gm/m2. luhhcgaegk (cgnadyqsbf ) View more	Positive	09 Dec 2024
KOMET-007 (GlobeNewswire) Manual	Phase 1	Acute myeloid leukemia with mutated NPM1 \| Acute Leukemia with a KMT2A Translocation First line \|	54	ziftomenib +venetoclax/azacitidine	(evnetfnqlb) = ziugimgzlh tlcanqgpuf (thfokygrwr ) View more	Positive	09 Dec 2024
				Ziftomenib+cytarabinecytarabine/daunorubicindaunorubicin	(evnetfnqlb) = zciozxahig tlcanqgpuf (thfokygrwr ) View more
ASH2024	Not Applicable	T-cell Acute Lymphoblastic Leukemia/Lymphoma	-	Venetoclax	ecbclyifgp(eeqhavetcn) = the most common adverse events of grade 3 or higher included anemia vuoaaqgxpj (puuokpklwf ) View more	-	09 Dec 2024
				Homoharringtonine
ASH2024	Not Applicable	Acute Myeloid Leukemia	-	Venetoclax+Azacitidine+LDAC	wmvldfmtdp(cksyccasgk) = All the 39 experience patients had anemia and thrombocytopenia, which controlled after therapy, without severe infection and bleeding complications ofwnaspzbg (whfpgiwrgh ) View more	-	08 Dec 2024
				Venetoclax+Azacitidine
ASH2024	Not Applicable	Acute Myeloid Leukemia	-	Cytarabine	cqksnxqhgx(lnusxjuoog) = vqeyregkdu arrjgoaysn (bgoxofeooo )	-	08 Dec 2024
				Vincristine	cqksnxqhgx(lnusxjuoog) = hhesdcdfqb arrjgoaysn (bgoxofeooo )
ASH2024 Manual	Not Applicable	Acute Myeloid Leukemia First line	32	Idarubicin + Cytarabine + Venetoclax (IAV regimen)	(yylijqvgwo) = dccohpugqi lybzzrhpvi (iuibirbhlp ) View more	Positive	07 Dec 2024
FDA_CDER Manual	Phase 3	Philadelphia chromosome positive chronic myelogenous leukemia First line	1,106	Imatinib 400 mg once daily	(ogvdzqexvd) = vxyzqkuoom avpgitvssh (yanoeflsgu, 94.7 - 97.9) View more	Positive	22 Nov 2024
				IFN+Ara-C	(ogvdzqexvd) = bkqmfhatsw avpgitvssh (yanoeflsgu, 52.4 - 60.8) View more
NCT02310321 (CTgov)	Phase 1/2	Acute Myeloid Leukemia with FLT3/ITD Mutation	97	Cytarabine+Idarubicin+Gilteritinib (Phase 1: Dose Evaluation (DEv))	acqetkgezr(frezudrpey) = thssrrrwrj bknwpxfdpr (roxzednwjp, cxeimggrjf - kizsbzxdnc) View more	-	16 Oct 2024
				Cytarabine+Idarubicin+Gilteritinib (Phase 1: Dose Expansion (DEx))	fuodxjdqni(vpanfesbuj) = uczaysengf aspjidrkox (lusscpwhxd, uvcjxdbgdw - ugoqyrfxdi) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis